725-P: Effect of a Continuous Remote Care Intervention on Glycemic Target Achievement and Medication Use among Adults with T2D: A Post Hoc Analysis

Abstract

Background: Only about half of patients with type 2 diabetes (T2D) achieve the HbA1c <7% target, and maintenance often requires medication intensification over time. A continuous remote care intervention (CCI) including ketosis via carbohydrate restriction nutrition therapy was previously demonstrated to improve glycemic outcomes in adults with T2D for at least two years; here, we assess the proportion of patients meeting glycemic targets and accompanying medication use. Methods: Adults with T2D selected to receive the CCI (n=262) or usual care (UC; n=87). We utilized GEE to assess change in the proportion of patients at HbA1c <7% target and accompanying medication use at 1 and 2 years compared to baseline. Analyses were conducted among completers and on an intent-to-treat basis with missing data considered as missing the HbA1c target. Results: The proportion of CCI patients meeting the HbA1c <7% target significantly increased at 1 and 2 years (Table 1). A similar improvement trend was seen among those treated with a single drug (monotherapy), and the proportion of patients at target without the use of medication approximately tripled. No changes occurred among patients who selected UC. Conclusion: This suggests the CCI is an effective means to help more patients achieve the HbA1c <7% target, including with monotherapy or no medication, among those who choose it. Disclosure S.J. Athinarayanan: Employee; Self; Virta Health Corp. R.N. Adams: Employee; Self; Virta Health Corp. S. Hallberg: Advisory Panel; Self; Atkins Nutritionals, Inc. Employee; Self; Virta Health Corp. Stock/Shareholder; Self; Virta Health Corp. S. Phinney: Advisory Panel; Self; Atkins Nutritionals, Inc. Stock/Shareholder; Self; Beyond Obesity LLC (publishing), Virta Health Corp. A. McKenzie: Employee; Self; Virta Health Corp. Stock/Shareholder; Self; Virta Health Corp.